From bench to clinic and back: Perspective on the 1 st IQPC Translational Research conference
- PDF / 201,126 Bytes
- 8 Pages / 610 x 792 pts Page_size
- 55 Downloads / 167 Views
BioMed Central
Open Access
Review
From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference Heidi Hörig*1 and William Pullman2 Address: 1Columbia University Medical Center, Division of Surgical Science NY 10032 USA and 2Sanofi-Aventis, Bridgewater NJ 08807 USA Email: Heidi Hörig* - [email protected]; William Pullman - [email protected] * Corresponding author
Published: 20 December 2004 Journal of Translational Medicine 2004, 2:44
doi:10.1186/1479-5876-2-44
Received: 09 December 2004 Accepted: 20 December 2004
This article is available from: http://www.translational-medicine.com/content/2/1/44 © 2004 Hörig and Pullman; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Translational Research (TR) provides a set of tools and communication context for scientists and clinicians to optimize the drug discovery and development process. In the proceedings of a Princeton conference on this timely topic, the strengths and needs of this developing field were debated. Outcomes and key points from these discussions are summarized in this article which covers the topics of defining what we mean by translational research (both theoretically and in operational terms), ways in which to engender the TR mindset and embed it in organizations such as the pharmaceutical industry in order to optimize the impact of available technologies (including imaging methods), the scientific basis and under-pinnings of TR including genomics knowledge, information sharing, as well as examples of application to drug discovery and development. Importantly, it should be noted that collaborations and communications between the stakeholders in this field, namely academia, industry and regulatory authorities, must be strengthened in order for the promise of TR to be delivered as better therapies to patients.
Introduction There are many challenges facing pharmaceutical companies in the post-genome era not least of which is declining productivity and innovation. Not surprisingly, there is agreement between Industry, Academia and Regulatory communities that the drug discovery and development process needs to change in order to meet the future needs of patients with effective and desirable drugs. A key part of the strategic solution is to leverage the application of TR principles and practices, which if implemented will go a long way towards addressing the challenge posed by FDA's Critical Path Initiative [1] (for more detail on this initiative see section on "Optimizing the Impact of TR" and http://www.fda.gov/oc/initiatives/criticalpath/white paper.pdf). Successful drug development requires satisfying a matrix of domains from relevance to the disease and
the drug-ability of the target through feasibility and convenience of drug delivery, demonstra
Data Loading...
